ANO1 and prostate carcinoma: The integration of molecular biology, pharmacology, and oncogenesis in investigating TMEM16A marks a notable progress in our comprehension of cancer processes, establishing TMEM16A as a noteworthy target for upcoming therapies in prostate cancer.